Hepatitis C treatment gets the FDA go-ahead
Steve’s breakdown: Biopharmaceutical company AbbVie spends over $300 million in advertising and judging by the results this treatment is getting, they’ll be throwing money at this brand.
The new indication for Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) will allow it to be used for patients with genotype 1b chronic hepatitis C and compensated cirrhosis.
“We are constantly striving to advance clinical care for patients living with chronic hepatitis C,” Dr. Michael Severino, EVP research and development and chief scientific officer at AbbVie, said. “This approval is especially significant because patients with chronic HCV with compensated cirrhosis are among the tough to treat, and in our study VIEKIRA PAK demonstrated 100 percent cure rates in GT1b patients without the use of ribavirin.”